NASDAQ:CYTX

Cytori Therapeutics (CYTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.10
$2.24
50-Day Range
$0.20
$0.21
52-Week Range
$0.20
$0.75
Volume
65,498 shs
Average Volume
915,302 shs
Market Capitalization
$47.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CYTX stock logo

About Cytori Therapeutics Stock (NASDAQ:CYTX)

Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.

CYTX Stock News Headlines

Checkpoint Therapeutics Inc (CKPT)
Sage Therapeutics Inc SAGE
The Crypto 9-5 Escape Plan
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
5 Biotech Stocks Under $10 Blasting Higher
8 Stocks Under $10 Ripping Higher
See More Headlines
Receive CYTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2019
Today
5/12/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CYTX
CUSIP
23283K10
Fax
N/A
Employees
37
Year Founded
N/A

Profitability

Net Income
$-12,630,000.00
Net Margins
-242.60%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.67 million
Book Value
$0.35 per share

Miscellaneous

Free Float
N/A
Market Cap
$47.87 million
Optionable
Not Optionable
Beta
1.96
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Marc H. Hedrick
    President, Chief Executive Officer & Director
  • Gary S. Titus
    Chief Financial Officer
  • Mark T. Marino
    Chief Medical Officer & Senior Vice President
  • John K. Fraser
    Chief Scientist
  • Russ Havranek
    VP-Global Marketing & Business Development

CYTX Stock Analysis - Frequently Asked Questions

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) released its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.02. The biotechnology company had revenue of $0.70 million for the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative trailing twelve-month return on equity of 272.70%.

When did Cytori Therapeutics' stock split?

Cytori Therapeutics shares reverse split on the morning of Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cytori Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), Exelixis (EXEL), Athersys (ATHX), BCE (BCE), Celldex Therapeutics (CLDX), Synergy Pharmaceuticals (SGYP) and Novavax (NVAX).

This page (NASDAQ:CYTX) was last updated on 5/12/2024 by MarketBeat.com Staff

From Our Partners